FTC Clears $338M Baxter-Prism Pharmaceuticals Deal
The Federal Trade Commission on Friday granted an early termination of its antitrust review of Baxter International Inc.'s purchase of Prism Pharmaceuticals Inc. in a deal worth up to $338 million...To view the full article, register now.
Already a subscriber? Click here to view full article